Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 11/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664806 | 0.90 | HTR2A (0.37) | RENHTR2AKDM1AHDAC8HDAC6 | |
| SCHEMBL663046 | 0.88 | REN (0.42) | RENCYP3A4HTR2AKCNH2HSD11B1 | |
| SCHEMBL1752126 | 0.86 | REN (0.43) | RENCYP3A4HTR2AKCNH2TACR1 | |
| SCHEMBL1751809 | 0.84 | REN (0.45) | RENCYP3A4KCNH2TACR1 | |
| SCHEMBL1750635 | 0.84 | PTGDR2 (0.45) | RENCYP3A4HTR2AKCNH2HSD11B1 | |
| SCHEMBL1750822 | 0.84 | REN (0.41) | RENCYP3A4HTR2ATACR1KDM1A | |
| SCHEMBL1751224 | 0.83 | REN (0.45) | RENCYP3A4HTR2AKCNH2 | |
| SCHEMBL1751560 | 0.83 | REN (0.40) | RENCYP3A4HTR2AKCNH2KDM1A | |
| SCHEMBL4526670 | 0.83 | REN (0.43) | RENCYP3A4HTR2ATACR1HSD11B1 | |
| SCHEMBL662616 | 0.83 | PSMB5 (0.39) | RENCYP3A4KCNH2PSMB5TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885CYP3A4 774/4885HTR2A 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.